s='''
PMID- 31131053{PMID号}
OWN - NLM
STAT- In-Data-Review
LR - 20190527
IS - 1838-7640 (Electronic)
IS - 1838-7640 (Linking)
VI - 9
IP - 9
DP - 2019{年}
TI - Regulation of ezrin tension by S-nitrosylation mediates non-small cell lung
cancer invasion and metastasis.
PG - 2555-2571
LID - 10.7150/thno.32479 [doi]【可能会有两个LID，选择后面有[doi]的】{DOI号}
AB - Cancer invasion and metastasis depend on accurate and rapid modulation of both
chemical and mechanical activities. The S-nitrosylation (SNO) of membrane
cytoskeletal cross-linker protein ezrin may regulate the malignant process in a
tension-dependent manner. Methods: The level of nitrosylated ezrin in non-small
cell lung cancer (NSCLC) tissues and A549 cell line were evaluated by
biotin-switch assay. A few cysteine mutated plasmids of ezrin were used to
identify active site for SNO. Newly designed ezrin or mutated-ezrin tension
probes based on Forster resonance energy transfer (FRET) theory were applied to
visually observe real-time tension changes. Cytoskeleton depolymerizing and motor
molecular inhibiting experiments were performed to reveal the alternation of the
mechanical property of ezrin after SNO. Transwell assays and xenograft mouse
model were used to assess aggressiveness of A549 cells in different groups.
Fluorescent staining was also applied to examine cellular location and
structures. Results: High inducible nitric oxide synthase (iNOS) levels were
observed to induce ezrin-SNO, and then promote malignant behaviors of NSCLC cells
both in vitro and in vivo. Cys(117) was identified as the only active site for
ezrin-SNO. Meanwhile, an increased level of ezrin tension was observed after
iNOS-induced SNO. Enhanced ezrin tension was positively correlated with
aggressiveness of NSCLC. Moreover, Microfilament (MF) forces instead of
microtubule (MT) forces played dominant roles in modulating ezrin tension,
especially after ezrin nitrosylation. Conclusion: This study revealed a
SNO-associated mechanism underlying the mechanical tension of ezrin. Ezrin-SNO
promotes NSCLC cells invasion and metastasis through facilitating mechanical
transduction from the cytoskeleton to the membrane. These studies implicate the
therapeutic potential by targeting ezrin in the inhibition NSCLC invasion and
metastasis. {摘要}
FAU - Zhang, Xiaolong
AU - Zhang X
AD - State Key Laboratory Cultivation Base for TCM Quality and Efficacy, School of
Medicine and Life Science, Nanjing University of Chinese Medicine, Nanjing
210023, Jiangsu, PR China.
AD - Key Laboratory of Drug Target and Drug for Degenerative Disease, Nanjing
University of Chinese Medicine, Nanjing 210023, Jiangsu, PR China.
FAU - Li, Guangming
AU - Li G
AD - Department of Anesthesiology, Huaian First People's Hospital, Nanjing Medical
University, Huaian 223001, Jiangsu, PR China.
FAU - Guo, Yichen
AU - Guo Y
AD - Department of Surgery and Biomedical Engineering, University of Alabama at
Birmingham (UAB), Birmingham, Alabama. 35294, USA.
FAU - Song, Ying
AU - Song Y
AD - Department of Respiratory Medicine, The First Affiliated Hospital of Nanjing
Medical University, Nanjing 210029, PR China.
FAU - Chen, Linlin
AU - Chen L
AD - State Key Laboratory Cultivation Base for TCM Quality and Efficacy, School of
Medicine and Life Science, Nanjing University of Chinese Medicine, Nanjing
210023, Jiangsu, PR China.
AD - Key Laboratory of Drug Target and Drug for Degenerative Disease, Nanjing
University of Chinese Medicine, Nanjing 210023, Jiangsu, PR China.
FAU - Ruan, Qinli
AU - Ruan Q
AD - State Key Laboratory Cultivation Base for TCM Quality and Efficacy, School of
Medicine and Life Science, Nanjing University of Chinese Medicine, Nanjing
210023, Jiangsu, PR China.
AD - Key Laboratory of Drug Target and Drug for Degenerative Disease, Nanjing
University of Chinese Medicine, Nanjing 210023, Jiangsu, PR China.
FAU - Wang, Yifan
AU - Wang Y
AD - State Key Laboratory Cultivation Base for TCM Quality and Efficacy, School of
Medicine and Life Science, Nanjing University of Chinese Medicine, Nanjing
210023, Jiangsu, PR China.
AD - Key Laboratory of Drug Target and Drug for Degenerative Disease, Nanjing
University of Chinese Medicine, Nanjing 210023, Jiangsu, PR China.
FAU - Sun, Lixia
AU - Sun L
AD - Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210023,
Jiangsu, PR China.
FAU - Hu, Yunfeng
AU - Hu Y
AD - State Key Laboratory Cultivation Base for TCM Quality and Efficacy, School of
Medicine and Life Science, Nanjing University of Chinese Medicine, Nanjing
210023, Jiangsu, PR China.
AD - Key Laboratory of Drug Target and Drug for Degenerative Disease, Nanjing
University of Chinese Medicine, Nanjing 210023, Jiangsu, PR China.
FAU - Zhou, Jingwen
AU - Zhou J
AD - The First Clinical Medical College of Nanjing University of Chinese Medicine,
Nanjing, Jiangsu 210023, PR China.
FAU - Ren, Bin
AU - Ren B
AD - Department of Surgery and Biomedical Engineering, University of Alabama at
Birmingham (UAB), Birmingham, Alabama. 35294, USA.
FAU - Guo, Jun【如果最后一个作者有2个单位，2个单位都要，但是可以放在同一个单元格中】{通讯作者全名（优先选择地址里面有邮箱的，否则就选择最后一个作者）}
AU - Guo J
AD - State Key Laboratory Cultivation Base for TCM Quality and Efficacy, School of
Medicine and Life Science, Nanjing University of Chinese Medicine, Nanjing
210023, Jiangsu, PR China. {通讯作者单位}
AD - Key Laboratory of Drug Target and Drug for Degenerative Disease, Nanjing
University of Chinese Medicine, Nanjing 210023, Jiangsu, PR China.
LA - eng
PT - Journal Article
DEP - 20190413{发表时间}
PL - Australia
TA - Theranostics
JT - Theranostics{期刊全名}
JID - 101552395
PMC - PMC6525990
OTO - NOTNLM
OT - FRET
OT - ezrin S-nitrosylation
OT - invasion
OT - metastasis
OT - non-small cell lung cancer【所有OT，可以放在同一个单元格中】{关键词}
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2019/05/28 06:00
MHDA- 2019/05/28 06:00
CRDT- 2019/05/28 06:00
PHST- 2018/12/21 00:00 [received]
PHST- 2019/03/18 00:00 [accepted]
PHST- 2019/05/28 06:00 [entrez]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2019/05/28 06:00 [medline]
AID - 10.7150/thno.32479 [doi] 【可能会有两个AID，选择后面有[doi]的】{DOI号2}
AID - thnov09p2555 [pii]
PST - epublish
SO - Theranostics. 2019 Apr 13;9(9):2555-2571. doi: 10.7150/thno.32479. eCollection
2019. {引文信息}
'''
import re
pmid=re.search("PMID- (\d+){",s)
print(pmid.group(1))
dp=re.search("DP\s+- (\d+){",s)
print(dp.group(1))
ti= re.search("TI\s+- ([\sa-zA-Z-\.]+)PG",s,re.M)
print(ti.group(1))
lid=re.search("LID\s+- ([\sa-zA-Z-\.\\0-9]+)\[",s)
print(lid.group(1))
ab=re.search("AB\s+- ([\sa-zA-Z-\.\\0-9\(\),:]+){",s,re.M)
print(ab.group(1))
fau=re.findall("FAU\s+- ([\sa-zA-Z,]+)$",s,re.M)
for x in fau:print(x)
ad= re.search("AD\s+- ([\sa-zA-Z0-9-\.,]+){",s,re.M)
print(ad.group(1))
dep=re.search("DEP - (\d+){",s)
print(dep.group(1))
jt=re.search("JT\s+- ([A-Za-z]+){",s)
print(jt.group(1))
ot=re.findall("OT\s+- ([A-Za-z- ]+)$",s,re.M)
for x in ot:print(x)
ot2=re.search("OT\s+- ([a-z]+\-[a-z]+\s+[a-z]+\s+[a-z]+\s+[a-z]+)",s)
print(ot2.group(1))
aid=re.findall("AID\s+- ([\sa-z0-9\.\/]+)",s)
for x in aid:print(x)
so=re.search("SO\s+- ([\sA-Za-z0-9\.\/:;\(\)-]+)",s,re.M)
print(so.group(1))
( 粤ICP备18085999号-1 | 粤公网安备 44051102000585号)
狗仔卡
发表于 2019-6-4 16:47:28
置顶卡
千斤顶
显身卡
楼主
。关于前面你提到的作者,是这样的要求：优先选择地址里面有邮箱的，否则就选择最后一个作者